• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NADROPARIN Drug Record

  • Summary
  • Interactions
  • Claims
  • NADROPARIN wikidata:Q20817257

    Alternate Names:

    drugbank:08813
    chemidplus:9041-08-1

    Drug Info:

    Drug Categories heparin (low molecular weight)
    Drug Groups investigational
    Drug Categories agents causing hyperkalemia
    Drug Categories heparin and similars
    (0 More Sources)

    Publications:

    Sustar et al., Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin., Blood Cells Mol. Dis.
    Nagy et al., 2009, The effect of LMWH (Nadroparin) on tumor progression., Pathol. Oncol. Res.
    Frydman, 1996, Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans., Haemostasis
    Davis et al., 1997, Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders., Drugs Aging
    Ludwig et al., 2006, The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo., Thromb. Haemost.
    Simonis et al., 2007, Affinity and kinetics of different heparins binding to P- and L-selectin., Semin. Thromb. Hemost.
  • NADROPARIN   SELP

    Interaction Score: 3.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16525583 17629851


    Sources:
    DrugBank

  • NADROPARIN   FOS

    Interaction Score: 3.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19261492 19757196


    Sources:
    DrugBank

  • NADROPARIN   SERPINC1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    potentiator

    Interaction Info:

    PMIDs:
    8707165 9108990


    Sources:
    DrugBank

  • NADROPARIN   MYC

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19261492 19757196


    Sources:
    DrugBank

  • DrugBank: DB08813

    • Version: 5.1.7

    Alternate Names:
    NADROPARIN DrugBank Drug Name
    Fraxiparine Drug Brand
    Fraxiparine Forte Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Sustar et al., Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin., Blood Cells Mol. Dis.
    Nagy et al., 2009, The effect of LMWH (Nadroparin) on tumor progression., Pathol. Oncol. Res.
    Ludwig et al., 2006, The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo., Thromb. Haemost.

  • Wikidata: wikidata:Q20817257

    • Version: 12-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21